MeiraGTx secures up to $400 million from Oberland Capital for gene therapy programs
The deal pairs up to $375 million in non-dilutive royalty financing with up to $25 million in equity to support bota-vec, AAV2-hAQP1, and AAV-AIPL1.
SEC filing
Latest
Tuesday, July 7
FDA approves supplemental application for Glenmark's Ryaltris nasal spray
The FDA cleared an efficacy-related supplement for the mometasone furoate and olopatadine hydrochloride combination spray on July 7, 2026.
Drugs@FDA
Tvardi's TTI-109 Phase 1 study confirms prodrug design and STAT3 target engagement
Tvardi Therapeutics reported that TTI-109 matched TTI-101's exposure with better tolerability, supporting plans to advance into Phase 2 pending funding.
SEC filing
MacroGenics closes sale of GMP manufacturing operations to Bora Pharmaceuticals
Bora paid $122.5 million for MacroGenics' Rockville facility and related assets, hiring about 140 former staff and taking over CDMO operations effective June 30, 2026.
SEC filing
Compass Pathways reports 26-week COMP006 data for psilocybin depression treatment
The company disclosed Part B results from its second Phase 3 trial of COMP360 in treatment-resistant depression on July 7, 2026, ahead of a planned Q4 NDA submission.
SEC filing
Sanofi's Nexviazyme meets all endpoints in infantile Pompe disease trial
The Baby-COMET phase 3 study supports a planned US regulatory submission for a label extension in the second half of 2026.
SEC filing
Theriva gets Spanish authorization for VIRAGE2 trial of VCN-01 in pancreatic cancer
The AEMPS cleared a Phase 2a trial testing more frequent dosing of VCN-01 in metastatic pancreatic cancer, building on survival data from the earlier VIRAGE study.
SEC filing
Alterity gets FDA meeting minutes backing Phase 3 path for ATH434 in MSA
FDA’s official End-of-Phase 2 minutes confirm a single pivotal trial plus confirmatory data could support approval, with Phase 3 targeted to start by year-end 2026.
SEC filing
ARS Pharmaceuticals replaces CEO, names Donn Casale to top job
The board installed President Donn Casale as CEO effective immediately, ousting Richard Lowenthal without cause.
SEC filing
Vor Biopharma board sees director change as Levin resigns, Zaccardelli named
Andrew Levin left the Vor Biopharma board effective immediately, and David Zaccardelli was named to fill the seat starting July 7, 2026.
SEC filing
CalciMedica appoints Zaytsev to board, expands to eight directors
Fred Middleton plans to retire from the board at the company's 2026 annual meeting, which will return the board to seven members.
SEC filing
Karuna/BMS opens Phase 3 KarXT relapse prevention trial in schizophrenia
CDT Equity amends loan terms, delays repayment start to July 10, 2026
The company restructured its convertible note with J.J. Astor & Co. to close the second funding tranche and push back the start of weekly repayments.
SEC filing
Monday, July 6
Immuron hires Pullan Consulting to find IMM-529 partner for C. diff drug
The Australian biopharma is seeking a licensing partner to fund Phase 2 development and commercialization of its investigational antibody therapy for Clostridioides difficile infection.
SEC filing
Incyte completes acquisition of Vega Therapeutics from Star Therapeutics
The deal brings VGA039, a Phase 3 antibody for von Willebrand disease, into Incyte's hematology portfolio for $1.25 billion upfront.
SEC filing
Molecular Partners updates on DLL3 and MSLN Radio-DARPin programs
The company reported ongoing dosing in the MP0712 Phase 1/2a trial and a new South African compassionate-care program using a different isotope pairing for DLL3 targeting.
SEC filing (2)
Vertex to acquire Crinetics for $85 a share in $10 billion deal
The all-cash acquisition adds Crinetics' newly launched acromegaly drug PALSONIFY and Phase 3 candidate atumelnant to Vertex's portfolio.
SEC filing
Can-Fite reports two updates: psoriasis enrollment milestone and pancreatic cancer safety data
Can-Fite completed enrollment for a Phase 3 psoriasis interim analysis and separately reported safety and survival data from a Phase 2a pancreatic cancer study of Namodenoson.
SEC filing (2)
Vertex to acquire Crinetics Pharmaceuticals for $85 per share in cash
The all-cash deal values Crinetics at $10 billion and adds endocrinology drugs PALSONIFY and atumelnant to Vertex's pipeline, with closing expected in Q3 2026.
SEC filing
Liminatus Pharma closes merger with InnocsAI after amending deal terms
The companies restructured merger consideration into common and preferred stock to close before a stockholder vote, completing the acquisition on July 2, 2026.
SEC filing
Nuvation Bio's underwriters fully exercise greenshoe on convertible notes offering
The exercise brings total notes sold to $287.5 million, with net proceeds now estimated at approximately $277.6 million.
SEC filing (3)
Perrigo revives executive severance policy amid CEO transition
The company reinstated a severance plan for top officers covering the period until a new permanent CEO has been in place for a year.
SEC filing (3)
Regeneron's Phase 2 olatorepatide obesity trial recruiting across five U.S. sites
Agomab registers Phase 2b trial of ontunisertib in fibrostenosing Crohn's disease
Kalaris Therapeutics board director resigns, new director elected
Morana Jovan-Embiricos departed the Kalaris Therapeutics board on July 3, 2026, with Laurie Keating set to join effective August 1, 2026.
SEC filing
Immunic board adds CEO Erik Lundgren as director after Tamar Howson's retirement
The move follows Howson's June 29 departure from the board and its compensation committee, which Immunic says was unrelated to any dispute.
SEC filing (2)
Quantum Cyber names Peter O'Rourke to lead drone unit, adds director Louis Buffalino
Quantum Cyber N.V. disclosed an executive employment agreement for its Quantum Drones Corporation subsidiary and a new board appointment, both effective July 1, 2026.
SEC filing
AbbVie updates 2026 EPS guidance for Q2 acquired IPR&D charge
AbbVie said a $291 million pretax charge tied to acquired IPR&D and milestones will cut second-quarter and full-year 2026 adjusted EPS guidance.
SEC filing
Gilead registers two Phase 3 trials of lenacapavir long-acting regimen with TAB and ZAB
Scilex signs term sheet for $100 million investment from Kazakhstan's iHolding Group
The binding term sheet, disclosed July 6, 2026, contemplates iHolding purchasing newly issued Scilex shares at $15.00 each, subject to due diligence and stockholder approval.
SEC filing (2)
Regeneron expects $127 million IPR&D charge in Q2 2026
The company said the charge, tied to licensing deals, will cut about $1.00 from per-share earnings under both GAAP and non-GAAP measures.
SEC filing
IGC Pharma discloses June 30 stock deal that settled debt to CEO and finance chief
A Form 8-K filed with the SEC confirms IGC Pharma's CEO and principal financial officer converted company debt into shares at $0.27 apiece, signed by the company on July 6, 2026.
SEC filing
United Therapeutics posts results for terminated Phase 3 ralinepag CPET study
Amgen registers two Phase 3 extension trials for obesity drug maridebart cafraglutide
Pfizer recruiting Phase 4 rimegepant safety study in India for triptan-refractory migraine patients
Medicenna Therapeutics discloses Form D for private securities offering
The company reported a $2,343,400 offering with $253,458 already sold to three investors, filed with the SEC on July 6, 2026.
SEC filing
Bursa City Hospital completes retrospective study on inflammatory markers in aortic dissection
Prestige Consumer Healthcare launches $400 million notes offering to refinance 2028 debt
The company plans a private notes sale due 2034, with proceeds set to retire existing 5.125% notes due 2028, alongside a term loan amendment tied to the LaCorium acquisition.
SEC filing
Corbus Pharmaceuticals names Leonardo Viana Nicacio as chief medical officer
The appointment, effective August 3, 2026, comes as Corbus prepares to start a registrational trial of CRB-701 in oropharyngeal cancer this summer.
SEC filing
Oragenics appoints John Spencer as CFO, holds annual meeting with mixed votes
The Florida-based company named its Senior Controller as CFO effective July 1, 2026, while shareholders approved a discretionary reverse stock split at the June 29 annual meeting.
SEC filing
Compass Therapeutics registers Phase 2 study of CTX-471 in NCAM-positive neuroendocrine tumors
Yarrow Bioscience registers Phase 2 trial of YB-101 in Graves' Disease
Vicore Pharma names Rob Slack chief scientific officer
Slack, formerly of GSK, replaces Johan Raud, who moves to senior advisor as Vicore develops buloxibutid for IPF.
SEC filing
AbCellera appoints Lynn Seely to board of directors
The company named Seely, former Myovant and Medivation chief, an independent Class III director effective June 30, 2026.
SEC filing
Agenus extends 2015 notes and warrant terms, adds new warrants for noteholders
Agenus pushed back the maturity of $5.09 million in senior subordinated notes and extended multiple warrant expirations while issuing new warrants to existing noteholders.
SEC filing